Association of RAAS inhibitors on osteoporosis and fracture risk in the hypertensive population–A prospective population-based cohort study in Lanzhou, China

Autor: Hongtao Yin, Mengdi Yang, Weiming Sun, Ruixing Zhang, Donghu Zhen, Xulei Tang

Publikováno v: BMC Musculoskeletal Disorders, Vol 25, Iss 1, Pp 1-15 (2024)

Abstract Background Renin-angiotensin-aldosterone system (RAAS) inhibitors appear to benefit bone tissue in antihypertensive treatment. However, the association between RAAS inhibitors and bone metabolism was inconsistent. Methods and study design Ba

Externí odkaz: https://doaj.org/article/5a80df469b604cd3b4a7691491024ede

RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives

Autor: Mykola Khalangot, Nadiia Sheichenko, Vitaly Gurianov, Tamara Zakharchenko, Victor Kravchenko, Mykola Tronko

Publikováno v: Frontiers in Endocrinology, Vol 14 (2023)

PurposeThe effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in combination with COVID-19 and diabetes mellitus (DM) remains unknown. We assessed the risk of death in COVID-19 inpatients based on the presence or absence of DM, arterial

Externí odkaz: https://doaj.org/article/b8107d0c85b045eb962754791fb144fc

Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one

Autor: Jorge Gonçalves, Catarina D. Santos, Paula Fresco, Fernando Fernandez-Llimos

Publikováno v: Revista Portuguesa de Cardiologia, Vol 43, Iss 4, Pp 221-222 (2024)

Externí odkaz: https://doaj.org/article/c6bf5cdaf8a24c4b8db5c246556e2f7c

COVID-19 and RAAS inhibitors: is there a final conclusion?

Autor: Talebi-Taher, Mahshid¹ mtalebitaher2000@yahoo.com, Najafi, Mohammad Hosein², Behzad, Shima²

Publikováno v: Iranian Journal of Microbiology. Dec2021, Vol. 13 Issue 6, p728-736. 9p.

Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one.

Autor: Gonçalves J; Laboratório de Farmacologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal; Mechanistic Pharmacology and Pharmacotherapy Unit, UCIBIO-i4HB, Faculty of Pharmacy, University of Porto, Porto, Portugal. Electronic address: jgoncalves@ff.up.pt., Santos CD; Laboratório de Farmacologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal., Fresco P; Laboratório de Farmacologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal; Mechanistic Pharmacology and Pharmacotherapy Unit, UCIBIO-i4HB, Faculty of Pharmacy, University of Porto, Porto, Portugal., Fernandez-Llimos F; Laboratório de Farmacologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal; Mechanistic Pharmacology and Pharmacotherapy Unit, UCIBIO-i4HB, Faculty of Pharmacy, University of Porto, Porto, Portugal.

Publikováno v: Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology [Rev Port Cardiol] 2024 Apr; Vol. 43 (4), pp. 221-222. Date of Electronic Publication: 2023 Oct 31.